QEL-005 for scleroderma, diffuse

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 16 Mar 2026: Trial registered, NCT07473154
  2. 10 Apr 2026: Trial started, NCT07473154

The trials

NCT07473154: Controlling Hyperactive Immunity With Long-lived Lymphocytes

State
Under way
Phase
Phase 1 and Phase 2
People
16 planned
Started
10 Apr 2026
Primary completion
Aug 2028
Arms
Dose Escalation, Dose Expansion
Results
None posted
  1. 16 Mar 2026: Trial registered
  2. 10 Apr 2026: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.